Publications by authors named "Nalina Dronamraju"

Claim this Profile
C
CPX-351 vs. conventional chemotherapy cardiotoxicity in high-risk AML: a post hoc phase III trial analysis.
Joshua D Mitchell, Michael Pfeiffer, John Boehmer, John Gorcsan, Shunsuke Eguchi, Nalina Dronamraju

Cardiooncology· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study.
Austin G Stack, David Han, Ronald Goldwater, Susanne Johansson, Nalina Dronamraju

J Clin Endocrinol Metab· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Intensive Urate Lowering With Combined Verinurad and Febuxostat on Albuminuria in Patients With Type 2 Diabetes: A Randomized Trial.
Austin G Stack, Nalina Dronamraju, Joanna Parkinson, Susanne Johansson, Eva Johnsson

Am J Kidney Dis· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
Juan P Frias, Guillermo Gonzalez-Galvez, Eva Johnsson, Jill Maaske, Marcia A Testa, Nalina Dronamraju

Diabetes Obes Metab· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
Lars Johansson, Paul D Hockings, Eva Johnsson, Nalina Dronamraju, Jill Maaske

Diabetes Obes Metab· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulphonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, Phase 3 trial.
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Ricardo Garcia-Sanchez, Nalina Dronamraju

Diabetes Obes Metab· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin Plus Saxagliptin Add-on Therapy Compared With Insulin in Patients With Type 2 Diabetes Poorly Controlled by Metformin With or Without Sulfonylurea Therapy: A Randomized Clinical Trial.
Tina Vilsbøll, Ella Ekholm, Eva Johnsson, Nalina Dronamraju, Serge Jabbour

Diabetes Care· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.
Dirk Müller-Wieland, Monika Kellerer, Katarzyna Cypryk, Dasa Skripova, Katja Rohwedder, Nalina Dronamraju

Diabetes Obes Metab· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
Rajeev Kumar, Robert A Hauser, Joseph Mostillo, Nalina Dronamraju, Ana Graf

Int J Neurosci· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mavoglurant in Parkinson's patients with l-Dopa-induced dyskinesias: Two randomized phase 2 studies.
Claudia Trenkwalder, Fabrizio Stocchi, Werner Poewe, Nalina Dronamraju, Chris Kenney

Mov Disord· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.
Jeffrey Cummings, Murat Emre, Dag Aarsland, Sibel Tekin, Nalina Dronamraju

J Alzheimers Dis· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson's disease.
Robert A Hauser, Michel Panisset, Giovanni Abbruzzese, Linda Mancione, Nalina Dronamraju

Mov Disord· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis